DC-CIK细胞免疫治疗联合化疗治疗晚期卵巢癌的效果及对免疫功能的影响

彭娟　崔慢慢

[摘要] 目的 探討树突细胞-细胞因子诱导的杀伤细胞（DC-CIK）免疫治疗联合化疗治疗晚期卵巢癌的效果及对免疫功能的影响。 方法 按照随机数字表法将2015年1月～2017年12月成都市新都区人民医院收治的70例晚期卵巢癌患者分为两组，对照组（n = 35）接受紫杉醇联合顺铂化疗，观察组（n = 35）在对照组治疗方案基础上联合DC-CIK免疫治疗。治疗3个疗程，随访6个月后比较两组患者临床治疗效果，并比较治疗前后两组患者免疫功能指标（CD3+、CD4+、CD8+、CD19、CD16+CD56+），记录并比较两组患者治疗过程中的不良反应。 结果 随访6个月后，观察组疾病控制率、客观缓解率均高于对照组，差异有统计学意义（P < 0.05）。观察组肝功能损害、骨髓抑制发生率均低于对照组，且观察组总不良反应总发生率低于对照组，差异有统计学意义（P < 0.05）。两组患者治疗后CD3+、CD4+、CD19、CD16+CD56+高于治疗前，CD8+低于治疗前，且观察组治疗后CD3+、CD4+、CD19、CD16+CD56+高于对照组，CD8+低于对照组，差异有统计学意义（P < 0.05）。 结论 DC-CIK细胞免疫治疗联合化疗能显著提高临床治疗效果，增强患者免疫功能，且不良反应少，值得临床推广。

[关键词] DC-CIK细胞免疫治疗;化疗;晚期卵巢癌;临床疗效;免疫功能

[中图分类号] R737.31          [文献标识码] A          [文章编号] 1673-7210（2019）06（b）-0059-04

Effect of DC-CIK cellular immunotherapy combined with chemotherapy on clinical efficacy and immune function in patients with advanced ovarian cancer

PENG Juan1   CUI Manman2

1.Department of Obstetrics and Gynecology， Xindu District People′s Hospital of Chengdu， Sichuan Province， Chengdu   610501， China; 2.Department of Gynaecology， Sichuan Provincial People′s Hospital， Sichuan Province， Chengdu   610072， China

[Abstract] Objective To explore the effect of dendritic cell-cytokine induced killer cell （DC-CIK） immunotherapy combined with chemotherapy for patients with advanced ovarian cancer and its influence on immune function. Methods A total of 70 patients with advanced ovarian cancer in Xindu District People′s Hospital of Chengdu from January 2015 to December 2017 was divided into two groups according to the random number table method. The control group （n = 35） was treated with Paclitaxel combined with Cisplatin， and the observation group （n = 35） was treated with DC-CIK immunotherapy on the base of control group. Continuous treatment for three courses， and follow up for 6 months， the clinical efficacy between two groups was compared. The comparisons of immune function indexes such as CD3+， CD4+， CD8+， CD19， CD16+CD56+ between two groups before and after treatment was conducted. The adverse reactions during the course of treatment were recorded and compared between the two groups. Results Six months after followed up， the disease control rate and objective remission rate in the observation group were higher than those in the control group， the differences were statistically significant （P < 0.05）. The liver dysfunction and bone marrow suppression in the observation group were respectively lower than those in the control group， and the total incidence of adverse reactions in the observation group was lower than that in the control group， the differences were statistically significant （P < 0.05）. After treatment， the levels of CD3+， CD4+， CD19 and CD16+CD56+ in two groups were significantly higher than those before treatment， and CD8+ level was lower than that before treatment， and the levels of CD3+， CD4+， CD19 and CD16+CD56+ in the observation group were higher than those in the control group， while the CD8+ level in the observation group was lower than that in the control group， the differences were statistically significant （P < 0.05）. Conclusion DC-CIK cell immunotherapy combined with chemotherapy can significantly improve the clinical efficacy and enhance immune function， which has fewer adverse reactions and worthy of clinical promotion.